Therapy for chronic migraine — a condition that’s been notoriously difficult-to-treat and which often leads to significant direct and indirect health care costs — has been upended with the recent approval of three injectable monoclonal antibody products in a new preventive medication class that’s significantly more effective than older preventive migraine drugs, a researcher says.
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.